Advertisement

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Welcome and Introduction to Vi3C

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Advertisement

Advertisement




Sep
04
Today In Oncology
Prostate Cancer NRG-GU005 Defines Trade-Offs Between SBRT and Moderately Hypofractionated IMRT
ADC/Immunotherapy Combination Shows Activity in Treatment-Resistant Nasopharyngeal Carcinoma
Hypofractionated Salvage Radiotherapy Evaluated After Prostatectomy for Biochemical Recurrence
Dual Oral Regimen Shows Encouraging Activity in KRAS G12C–Mutated Metastatic Colorectal Cancer
Researchers Define Molecular Prognostic Subgroups in Therapy-Related Myeloid Neoplasms
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo